Ignite Creation Date:
2024-05-06 @ 10:48 AM
Last Modification Date:
2024-10-26 @ 12:35 PM
Study NCT ID:
NCT03356080
Status:
UNKNOWN
Last Update Posted:
2017-11-29
First Post:
2017-11-09
Brief Title:
DLAAG in the Treatment of Acute Myeloid Leukemia AML and Myelodysplastic Syndrome With Blast Excess
Sponsor:
Shanghai Tong Ren Hospital
Organization:
Shanghai Tong Ren Hospital
Study Overview
Official Title:
Clinical Efficacy and Safety of DLAAG Protocol in the Treatment of RefractoryRelapse of Acute Myeloid Leukemia AML and Myelodysplastic Syndrome With Blast Excess a Multicenter Single-arm Prospective Clinical Study
Status:
UNKNOWN
Status Verified Date:
2017-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate of the clinical efficacy and safety of DLAAG protocol in the treatment of acute myeloid leukemia AML and myelodysplastic syndrome with blast excess
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None